Table 3.

Association of the expression level of molecular biomarkers with PFS/OS

Molecular biomarkers	High-grade serous carcinoma			Clear cell carcinoma			P e value
	Cases (%)	P(OS)	P(PFS)	Cases (%)	P(OS)	P(PFS)
EGFR	113(100)	0.017	0.042	92(100)	0.012	0.267	0.195
Negative	82(72.6)			59(64.1)
Positive	31(27.4)			33(35.9)
HER2	113(100)	0.938	0.475	95(100)	0.001	0.200	0.006
Negative	110(97.3)			83(87.4)
Positive	3(2.7)			12(12.6)
PTEN	113(100)	0.323	0.397	93(100)	0.160	0.061	0.716
Negative	99(87.6)			83(89.2)
Positive	14(12.4)			10(10.8)
AURKA	113(100)	0.006	0.382	95(100)	0.022	0.035	0.582
Negative	72(63.7)			57(60.0)
Positive	41(36.3)			38(40.0)
BRCA1	113(100)	0.017	0.032	92(100)	0.823	0.424	0.007
Negative	82(72.6)			50(54.3)
Positive	31(27.4)			42(45.7)
BRCA2	113(100)	0.743	0.500	94(100)	0.466	0.929	0.054
Negative	101(89.4)			75(79.8)
Positive	12(10.6)			19(20.2)
PD-L1	113(100)	0.037	0.159	95(100)	0.773	0.425	0.064
Negative	99(88.4)			75(78.9)
Positive	13(11.6)			20 (21.1)

A total of 113 cases of HGSC and 96 cases of CCC have both primary tumor immunohistochemistry results and survival information. However, the total number for each antibody does not add to up 96 in CCC group

^aChi-squared tests were performed for the difference of positive rates between HGSC and CCC groups

Bold value denotes P with statistical significance